- Home
- ATCX vs RNXT Comparison
ATCX vs RNXT Comparison
Compare ATCX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATCX | RNXT |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0M | 37.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATCX | RNXT |
|---|---|---|
| Price | $6.40 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 181.4K | ★ 204.6K |
| Earning Date | 03-16-2023 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $367,030.00 | ★ $928,000.00 |
| Revenue This Year | $109,631.07 | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.80 | $0.70 |
| 52 Week High | $47.16 | $1.45 |
Technical Indicators
Market Signals| Indicator | ATCX | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 49.98 |
| Support Level | $6.11 | $0.92 |
| Resistance Level | $7.39 | $1.08 |
| Average True Range (ATR) | 1.81 | 0.07 |
| MACD | -0.24 | -0.00 |
| Stochastic Oscillator | 5.18 | 52.38 |
Price Performance
Historical ComparisonAbout ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corporation, is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.